Printer Friendly

CEL-SCI CORPORATION ANNOUNCES ESTABLISHMENT OF PRODUCTION FACILITY

 ALEXANDRIA, Va., Feb. 11 /PRNewswire/ -- CEL-SCI Corporation (NASDAQ: CELI) today announced the signing of a manufacturing agreement with Chesapeake Biological Laboratories (CBL) of Baltimore. The agreement will lead directly to the production of the company's patent-protected drug, "BC-IL," for CEL-SCI's clinical trials.
 "BC-IL" is a mixture of natural human cytokines, produced in cell culture and purified. Cytokines are modulators of the human immune system. Maximilian de Clara, president of CEL-SCI Corporation, stated: "In nature, immune modulators always occur in combination. For this reason there should be a clear advantage to therapeutic use of a natural combination of cytokines, as opposed to using cytokine monotherapies. CEL-SCI has pioneered the development of such natural combinations of mixed cytokines. We expect BC-IL' to be a low cost, out-patient treatment with low toxicity, useful in the treatment of certain categories of cancer patients and other immune deficiency diseases."
 Geert Kersten, CEL-SCI Corporation chief operating officer, added: "The establishment of a product facility is an important and logical step in CEL-SCI's development program leading to future commercialization of BC-IL.' This facility will enable the company to supply multi-center clinical trials. The company intends to make the necessary regulatory filings and then initially to conduct a clinical study in advanced head and neck cancer patients."
 CEL-SCI Corporation has pioneered the development of natural cytokine mixtures (cocktails) for the treatment of cancers and other immune deficiency diseases. Its 50 percent-owned subsidiary, Viral Technologies, Inc. (Bethesda, Md.) is developing the HGP-30 AIDS Vaccine, based upon a highly conserved segment of the p17 core protein of the AIDS virus.
 -0- 2/11/93
 /CONTACT: Matt Haines of Strategic Growth International, 212-826-9622, or Daryll Strahl, 303-979-5735, both for CEL-SCI/
 (CELI)


CO: CEL-SCI Corporation; Chesapeake Biological Laboratories ST: Virginia IN: MTC SU:

KD -- DC002 -- 5516 02/11/93 08:28 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 11, 1993
Words:300
Previous Article:BP DIVIDEND ANNOUNCEMENT
Next Article:HOLLYWOOD COMES TO DETROIT VALENTINE'S WEEKEND
Topics:


Related Articles
CEL-SCI ENTERS PROCESS DEVELOPMENT AGREEMENT WITH ROGER WILLIAMS MEDICAL CENTER
CEL-SCI CORPORATION ANNOUNCES NEW LABORATORY FACILITY
CEL-SCI Corporation Starts New Cancer Trial in Canada
CEL-SCI Corporation Responds to Inquiries About the Status of Its Tuberculosis Program
CEL-SCI Corporation Secures Long-Term Manufacturing Commitment for Multikine(TM).
CEL-SCI Corporation Significantly Expands Facilities.
CEL-SCI Announces $15 Million Commitment For Cancer Drug Manufacturing Facility.
CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine.
CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008.
CEL-SCI Takes Delivery of New Manufacturing Facility.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters